Geron's Q2 revenue rises on RYTELO growth

Geron

05/08/2026 12:27

Overview
US biopharmaceutical firm's Q2 product revenue grew 11% quarter-on-quarter and 17% yr/yr
Company reiterated 2026 guidance for RYTELO net product revenue and operating expenses

Outlook
Company reiterates 2026 RYTELO net product revenue guidance of $220 mln to $240 mln
Geron expects 2026 total operating expenses of $230 mln to $240 mln
Company says existing cash and anticipated revenues sufficient to fund operations for foreseeable future

Result Drivers
RYTELO DEMAND - Co said Q2 results were driven by a third consecutive quarter of demand growth for RYTELO in LR-MDS patients
MORE ORDERING ACCOUNTS - Co said ordering accounts for RYTELO increased by roughly 8% in Q2 to about 1,575
INVENTORY EXPENSES - Co attributed increased net loss and operating expenses to non-cash inventory-related expenses

Company press release: ID:nGNX75h6zz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.02
 
Q2 Net Loss
 
$16.68 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Geron Corporation is $4.00, about 198.5% above its August 4 closing price of $1.34

Reuters Recommended Reads
Aug 4 - Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Aug 3 - Vertex Q2 revenue beats estimates on strong demand for cystic fibrosis therapies, lifts outlook
Aug 3 - Curium strikes up to $8 bln deal for radiopharma peer Lantheus

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)